Antiseptic imidazoles and ketones and nitrofurans

Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA , binding to the R site (PKAR), with an EC 50 of 6.5 nM and K d of 8 nM in Trypanosoma brucei . Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite

Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA , binding to the R site (PKAR), with an EC 50 of 6.5 nM and K d of 8 nM in Trypanosoma brucei . Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite

Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA , binding to the R site (PKAR), with an EC 50 of 6.5 nM and K d of 8 nM in Trypanosoma brucei . Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite

Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA , binding to the R site (PKAR), with an EC 50 of 6.5 nM and K d of 8 nM in Trypanosoma brucei . Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite

An imidazopyridine derivative that prevents Gli-dependent transcriptional activity (IC₅₀ = 30 nM) by inhibiting alcohol dehydrogenase 7 (IC₅₀ = 210 nM) and depolymerizing microtubules antiproliferative in a range of cancer

An imidazopyridine derivative that prevents Gli-dependent transcriptional activity (IC₅₀ = 30 nM) by inhibiting alcohol dehydrogenase 7 (IC₅₀ = 210 nM) and depolymerizing microtubules antiproliferative in a range of cancer

An imidazopyridine derivative that prevents Gli-dependent transcriptional activity (IC₅₀ = 30 nM) by inhibiting alcohol dehydrogenase 7 (IC₅₀ = 210 nM) and depolymerizing microtubules antiproliferative in a range of cancer

KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activityIn VitroKIF18A-IN-6 (Compound 134: 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC

KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activityIn VitroKIF18A-IN-6 (Compound 134: 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC

KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activityIn VitroKIF18A-IN-6 (Compound 134: 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC

Methyl 2-iodobenzoate can be prepared from 2-iodobenzoic acid via esterification. It undergoes cobalt-catalyzed cyclization with aldehydes to form phthalide derivatives.

Methyl 4-bromobenzoate is a para -substituted aryl bromide. Mol­ecules of methyl 4-bromobenzoate are almost planar.